WO2005037296A1 - 抗コロナウイルス剤 - Google Patents
抗コロナウイルス剤 Download PDFInfo
- Publication number
- WO2005037296A1 WO2005037296A1 PCT/JP2003/014008 JP0314008W WO2005037296A1 WO 2005037296 A1 WO2005037296 A1 WO 2005037296A1 JP 0314008 W JP0314008 W JP 0314008W WO 2005037296 A1 WO2005037296 A1 WO 2005037296A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- coronavirus
- silver
- potassium
- carrier
- agent according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/08—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing solids as carriers or diluents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Definitions
- the present invention relates to an anti-coronavirus agent which has an effect on coronavirus and can be incorporated into plastics, paints and the like.
- the present invention relates to an anti-coronavirus product made from a fiber or a resin containing an anti-coronavirus agent.
- SARS acute acute respiratory syndrome
- SARS coronavirus The acute acute respiratory syndrome (SARS) caused by the SARS coronavirus, which was particularly prevalent in Southeast Asia, has no vaccine and no radical treatment, so it is important to prevent infection.
- SARS infection may have spread not only through direct contact and droplet infection with infected individuals, but also through indirect contact through articles such as doorknobs and clothing touched by infected individuals.
- the SAR S coronavirus According to the first data on the stability and resistance of the SAR S coronavirus accumulated by the WHO Research Network, the SAR S coronavirus can survive in the outside world for several days under certain conditions. Therefore, it is considered that it is effective to always clean items that are frequently contacted by infected persons by disinfection, etc. to prevent infection.
- silver-based inorganic antibacterial agents are known as antibacterial agents having a long-lasting effect on bacteria.
- a silver-based inorganic antibacterial agent is an antibacterial agent in which silver is supported on an inorganic compound. It has high heat resistance and can be processed into various product forms before use.
- activated carbon supporting silver and silver or a silver compound see, for example, JP-A-49-16950
- silver-containing soluble glass for example, see No. 63-3-070707
- zeolite containing silver, copper and / or zinc for example, see JP-A-60-180002
- zirconium phosphate containing silver See, for example, JP-A-3-83905.
- these silver-based inorganic antibacterial agents are effective against coronaviruses such as SARS coronavirus.
- silver nitrate has activity against HSV (herpes simplex virus)-1 and 2, but has no activity on Vacciniavirus, Adenovirus, VSV, Poliovirus and HVJ (for example, RB See Thurman, CPGerba, "The Molecular Mechanisms of Copper and Silver ion Disinfection oi Bacteria and viruses", Critical Reviews in Environmental Control, 1989, Vol. 18, No. 4, p. 295-315. ).
- the present inventors have conducted intensive studies to solve the above-mentioned problems, and as a result, have found that the problems can be solved by using silver ions as an active ingredient and stably holding silver ions on a carrier. Completed.
- the present invention relates to an antiviral agent effective against coronavirus, comprising a carrier that stably holds silver ions.
- the present invention is a coronavirus-inactivating product containing an anti-coronavirus agent.
- the present invention also relates to a method for inactivating a coronavirus using the silver ion carrier of the present invention.
- An anti-coronavirus agent comprising a silver ion carrier.
- the silver ion carrier described above has the following formula (1), potassium titanate, potassium perlanate, potassium vanadate, potassium niobate, sodium tungstate, magnesium molybdate, calcium penborate, aluminokerate 1.
- the above-mentioned item 1 which is at least one member selected from the group consisting of: aluminum phosphate, nickel hexacyanoiron, sepiolite, montmorillonite, silica gel, zeolite,] 3-alumina, hydrous titanium oxide, hydroxyapatite, and vitreous carrier.
- Anti-coronavirus agent Ag a A b M2 c (P0 4) d - nH 2 0 (1)
- a method for inactivating a coronavirus which comprises using the anti-coronavirus agent described in any one of 1 to 4 above.
- a method for inactivating a coronavirus which comprises using the anti-coronavirus agent according to the above item 8, wherein the coronavirus is a SARS virus.
- the coronavirus in the present invention refers to a single-chain (+) RNA virus of the coronavirus family, and includes the genus Coronavirus and the genus Torovirus.
- IBV Infectious bronchitis virus
- FIP feline infectious peritonitis virus
- CMV canine coronavirus
- TGEV bush infectious gastroenteritis virus
- EqTV matrovirus
- the silver ion which is an active ingredient in the antiviral agent of the present invention, needs to be stably carried by the carrier.
- the term “stable” refers to a state of being always ionized without being affected by heat (for example, a temperature of 200 ° C or lower) and water (for example, humidity of 10 to 100%), and being in a non-ionic state such as a metal or an oxide. It means no change.
- Carrier which holds a silver ion stably in the present invention are those represented by the general formula represented by zirconium phosphate (1) and potassium titanate (K 2 T i 2 0 5 ), uranium acid Cali ⁇ beam (K 2 U 2 ⁇ 7), potassium vanadate (KV 2 ⁇ 8), potassium niobate (KNb_ ⁇ 8), sodium tungstate (Na 2 W 4 ⁇ 13), magnesium molybdate (Mg 2 Mo 2 0 7) oxyacid salt, pen evening borate such as (C a 2 (B 5 ⁇ 9) ( ⁇ _H)), graphite, crystalline ⁇ Ruminokei salt, crystalline aluminum phosphate, to Kisashiano iron salt, sepiolite (Mg 8 S i 12 O 30 (OH) 4 (H 2 ⁇ ) 4), silica gel, Zeoraito like substances such as montmorillonite, beta-alumina (a 1 2 ⁇ 3), hydrous titanium oxide (T I_ ⁇ 4
- a silver-containing zeolite-like substance, a silver-containing soluble glass, and the like are preferable because they can strongly support silver ions, and more preferably zirconium phosphate and silver-containing Zeolites and silver-containing fusing glasses are preferred.
- the above formula (1) can be obtained from the compound represented by the general formula (2).
- a ′ in the formula (2) is at least one metal ion selected from an alkali metal ion, an alkaline earth metal ion and an ammonium ion, X is 1 when A ′ is monovalent, and A is 2 When it is a value, it is 1/2.
- Preferred specific examples of the general formula (1) include the following.
- the silver ion contained in the silver ion carrier in the present invention is preferably 0.01 to 20% by mass, more preferably 0.05 to 15% by mass, and particularly preferably 0.1 to 5% by mass. is there. If the silver ion content of the silver ion carrier is less than 0.01% by mass, the antiviral effect against coronavirus may not be obtained. If the silver ion content is more than 20% by mass, coloring or economy of the silver ion carrier-containing material may occur. This is not preferred because it is disadvantageous in terms of the physical properties.
- the amount of silver ion eluted in water is preferably 0.5 // gZ liter / day or more (for example, with respect to 10 g of silver ion carrier). Days or more is preferable from the viewpoint of effect persistence.
- the silver ions are eluted too much, it is not preferable because more than enough silver ions are eluted in terms of effect, and it is also not preferable in terms of coloring the silver ion carrier-containing material.
- the particle size of the carrier is preferably 0.1 to 15 Am, more preferably 0.5 to 10 m. The use of such a particle size is preferable because the effectiveness can be effectively exhibited.
- the anti-coronavirus agent of the present invention comprises a zirconium phosphate represented by the general formula (1), potassium titanate, potassium uranate, potassium vanadate, potassium niobate, sodium niobate, sodium tungstate in a silver compound solution. (3) Add a carrier such as 3-alumina, hydrous titanium oxide, hydroxyapatite, etc. and stir. Can be obtained.
- silver halide conjugates examples include silver nitrate, silver sulfate, silver perchlorate, silver acetate, diamine silver nitrate, and diamine sulfate.
- the stirring can be carried out at 10 to 80 ° C., preferably at 40 to 60 for 1 to 50 hours, preferably for 5 to 24 hours, by a patch system or a continuous system. After the stirring, the carrier is washed with water and dried at 60 to 170 ° C.
- a water-soluble glass can be produced by incorporating silver oxide or the above-described silver compound. Since the anti-coronavirus agent of the present invention is a powder, it can be used as it is or after it has been processed.
- it can be used in a suspended state or as a molded product such as a granular material, a papermaking material, a pellet, a sheet, and a film. Further, it may be in the form of a porous body or a fibrous body. They can also be processed into paints, fabrics, nonwovens, foam sheets, paper, plastics, and inorganic plates.
- a molded product such as a granular material, a papermaking material, a pellet, a sheet, and a film.
- a porous body or a fibrous body may also be processed into paints, fabrics, nonwovens, foam sheets, paper, plastics, and inorganic plates.
- a silver zirconium phosphate-based support containing 3.7% by weight of silver is blended at a ratio of 1% by weight to the polyester resin for fibers, and melt-spun by a conventional method to obtain a 2-denier, 75-filament fiber.
- Coronavirus polyester multifilaments can be obtained.
- Fabrics and papers can be manufactured from the filaments.
- a silver zirconium phosphate-based support containing 3.7% by mass of silver was blended with the polypropylene resin at a ratio of 10% by mass to prepare a master batch of 10% by mass of the support.
- the carrier master patch is mixed with the polypropylene resin at a ratio of 10% by mass, and then injection-molded by a conventional method to obtain an anti-coronavirus polypropylene molded article. This article can be used as an anti-coronavirus product.
- a silver zirconium phosphate-based support containing 3.7% by mass of silver was blended at a ratio of 1% by mass with respect to the UV-cured acryl paint to prepare an anti-coronavirus UV paint.
- the anti-coronavirus SUS plate can be obtained by applying the anti-coronavirus paint to the SUS plate by a conventional method.
- Such anti-coronavirus paint can be used as an anti-coronavirus paint by applying it to walls, ceilings, floors and the like.
- An anti-corona consisting of 2 denier and 75 filaments is prepared by blending a silver zeolite Y-based carrier containing 2.0 mass% of silver with the polyamide resin for fiber at a ratio of 1 mass% and melt-spinning by a conventional method. Viral polyamide multifilaments can be obtained. Fabrics and papers can be manufactured from this filament.
- a silver zeolite A-based carrier containing 1.1% by mass of silver was added at a ratio of 10% by mass to ABS resin.
- a master patch of 10% by mass of the carrier was prepared. After mixing the carrier master batch at a ratio of 10% by mass with respect to the ABS resin, injection molding is performed by a conventional method to obtain an anti-coronavirus ABS molded article. This article can be used as an anti-coronavirus product.
- a silver glass-based support containing 1.0% by mass of silver is blended at a ratio of 0.5% by mass with respect to the polyester resin for fibers, and is melt-spun by a conventional method to obtain a 30-denier anti-coronavirus property.
- a polyester monofilament can be obtained.
- Cloth and paper can be manufactured from this filament.
- a silver glass-based carrier containing 1.0% by mass of silver was blended with the polystyrene resin at a ratio of 10% by mass to prepare a master batch of 10% by mass of the carrier.
- This carrier master batch is mixed with polystyrene resin at a ratio of 10% by mass, and then subjected to injection molding by a conventional method, whereby an anti-coronavirus polystyrene molded article can be obtained.
- This molded article can be used as an anti-mouthing virus product.
- a silver-silicone gel-containing carrier containing 1.1% by weight of silver is blended in a proportion of 1% by weight with respect to the polypropylene resin for fibers, and melt-spun by a conventional method to obtain a 30 denier anti-coronavirus polypropylene monofilament. Can be obtained. Cloth or paper can be manufactured from this filament.
- a silver silica gel-based carrier containing 1.1 mass% of silver was blended with the polyethylene resin at a ratio of 10 mass% to prepare a master batch of 10 mass% of the carrier.
- an anti-coronavirus polyethylene molded article can be obtained.
- This article can be used as an anti-coronavirus product.
- the product of the present invention can be used in various fields and places where it is desired to make coronavirus harmless. For example, medical field, cosmetics field, textile clothing field, bedding field, daily life Products, construction materials, ships, water treatment, etc.
- the anti-coronavirus agent of the present invention includes doors, floors, walls, and the like, and white coats, gloves, shoe covers, masks, curtains, sheets, evening owls, and fukins. Further, it may be incorporated as a filter in an air purifier, an air conditioner, or the like.
- TD 50 3000 g / m 1 ⁇ S AR S coronavirus virulence test
- Silver zirconium phosphate was added to the culture containing the 10 OTC ID 5 () amount of SARS coronavirus determined above at a concentration of 1500 g / m 1 and stirred for 4 hours and 6 hours. Then, these culture solutions were diluted 2-fold so that the concentration of silver zirconium phosphate was equivalent to 1500 to 23.4 ig / ml, to prepare a test solution. Each of these assays was placed in a VE RO E 6 monolayer forming plate (each concentration 4 holes used) 37 ° C, 5% C0 2, and cultured for 5-7 days. During this culture period, virus CPE was observed daily under a microscope, and the test was terminated when the CPE of the untreated control virus became 51% or more.
- a silver zirconium phosphate-based support containing 3.7% by weight of silver is blended at a ratio of 1% by weight with respect to the polyester resin for fiber, and is melt-spun by a conventional method to consist of 2 deniers and 75 filaments. An anti-coronavirus polyester multifilament was obtained.
- a master patch of 10% by mass of the carrier was prepared by mixing at a ratio of 10% by mass.
- One batch of the carrier master was mixed with the polypropylene resin at a ratio of 10% by mass, and injection molding was performed by a conventional method to obtain an anti-coronavirus polypropylene molded article.
- a silver zirconium phosphate-based support containing 3.7% by mass of silver was blended at a ratio of 1% by mass to the UV-curable acrylic paint to prepare an antibacterial UV paint.
- the antibacterial paint was applied to a SUS plate by a conventional method to obtain an anticoronavirus SUS plate.
- the anti-coronavirus agent using the silver ion carrier of the present invention is effective against coronavirus and has heat resistance and durability. From this, it can be used as an anti-coronavirus product in various forms by processing it into plastic.
- the use of the silver ion carrier of the present invention makes it possible to inactivate coronavirus existing or newly engrafted in a room or the like, so that infection can be prevented.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Agronomy & Crop Science (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Artificial Filaments (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/576,012 US20070026087A1 (en) | 2003-10-16 | 2003-10-31 | Anti-coronavirus agent |
EP03818872.8A EP1676582B1 (en) | 2003-10-16 | 2003-10-31 | Anti-coronavirus agent |
AU2003304507A AU2003304507A1 (en) | 2003-10-16 | 2003-10-31 | Anti-coronavirus agent |
JP2005509617A JPWO2005037296A1 (ja) | 2003-10-16 | 2003-10-31 | 抗コロナウイルス剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-356935 | 2003-10-16 | ||
JP2003356935 | 2003-10-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005037296A1 true WO2005037296A1 (ja) | 2005-04-28 |
Family
ID=34463231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/014008 WO2005037296A1 (ja) | 2003-10-16 | 2003-10-31 | 抗コロナウイルス剤 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20070026087A1 (ja) |
EP (1) | EP1676582B1 (ja) |
JP (1) | JPWO2005037296A1 (ja) |
CN (1) | CN100500162C (ja) |
AU (1) | AU2003304507A1 (ja) |
WO (1) | WO2005037296A1 (ja) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007106876A (ja) * | 2005-10-13 | 2007-04-26 | Tottori Univ | 抗ウィルス性塗料組成物および塗装物 |
US20070243263A1 (en) * | 2006-04-14 | 2007-10-18 | Agion Technologies, Inc. | Antiviral Methods |
JP2010505887A (ja) * | 2006-10-12 | 2010-02-25 | エヌエム テック ナノマテリアルズ マイクロディバイス テクノロジー リミテッド | 抗微生物性を有する組成物を含む材料、アイテム及び製品 |
JP2016190808A (ja) * | 2015-03-31 | 2016-11-10 | 住化エンバイロメンタルサイエンス株式会社 | 抗ウイルス組成物 |
WO2017150063A1 (ja) * | 2016-03-01 | 2017-09-08 | 東亞合成株式会社 | 抗ウイルス剤、コーティング組成物、樹脂組成物及び抗ウイルス製品 |
JP2018172306A (ja) * | 2017-03-31 | 2018-11-08 | 住化エンバイロメンタルサイエンス株式会社 | 抗ウイルス性コーティング剤 |
JP6884447B1 (ja) * | 2020-11-06 | 2021-06-09 | 一般財団法人新医療財団 | コロナウイルス(例えば、SARS−CoV−2)を含む広範な微生物に有用な抗微生物剤 |
JP2021181227A (ja) * | 2020-07-30 | 2021-11-25 | 大日本印刷株式会社 | 抗ウイルス性物品及び抗ウイルス性樹脂組成物 |
WO2022025136A1 (ja) * | 2020-07-30 | 2022-02-03 | 大日本印刷株式会社 | 抗ウイルス性物品及び抗ウイルス性樹脂組成物 |
JP2022027514A (ja) * | 2020-07-30 | 2022-02-10 | 大日本印刷株式会社 | 抗ウイルス性物品及び抗ウイルス性樹脂組成物 |
WO2022079997A1 (ja) * | 2020-10-15 | 2022-04-21 | Dr.C医薬株式会社 | 殺コロナウイルス剤並びにそれを用いた方法及び用途 |
WO2023021768A1 (ja) * | 2021-08-18 | 2023-02-23 | 株式会社ダイセル | 抗ウイルス性成形体およびその用途 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009156975A1 (es) * | 2008-06-25 | 2009-12-30 | Nanobiomatters, S. L. | Materiales nanocompuestos activos y el procedimiento para su obtención. |
US8231689B2 (en) | 2009-11-13 | 2012-07-31 | Warner Babcock Institute For Green Chemistry, Llc | Coloring composition containing an aromatic compound and an initiator |
US20110113571A1 (en) * | 2009-11-13 | 2011-05-19 | Warner Babcock Institute For Green Chemistry, Llc | Color composition containing an aromatic compound and tyrosinase |
US8118880B1 (en) | 2010-11-15 | 2012-02-21 | Warner Babcock Institute For Green Chemistry, Llc | Coloring composition containing L-DOPA and L-arginine and forming a non-covalent derivatization complex |
WO2013158509A1 (en) * | 2012-04-16 | 2013-10-24 | Bunge Amorphic Solutions Llc | Antimicrobial chemical compositions |
WO2016131459A2 (de) * | 2015-02-19 | 2016-08-25 | Paul Schaffrath | Verfahren zur inaktivierung von krankheitserregern mit elektrisch erzeugten silberionen |
EP4132467A4 (en) * | 2020-04-06 | 2024-04-10 | Ankit Agarwal | SILVER NANOPARTICLES FOR USE IN INHIBITING AND TREATMENT OF CORONAVIRUS INFECTIONS |
CN112890322B (zh) * | 2020-04-21 | 2023-04-07 | 中国科学院大连化学物理研究所 | 一种吸附灭活病毒口罩产品 |
EP3907261A1 (en) * | 2020-05-06 | 2021-11-10 | Hecosol GmbH | Use of antimicrobial coating |
CN112006031B (zh) * | 2020-08-25 | 2021-09-14 | 广东欧文莱陶瓷有限公司 | 一种陶瓷用抗菌剂、抗菌陶瓷及其制备方法 |
EP4299132A3 (en) | 2020-08-29 | 2024-02-21 | Portillo Rosado, Rosa Maria | Pharmaceutical composition containing a surfactant and natural plant extracts for preventing and treating coronavirus |
IT202000027390A1 (it) | 2020-11-16 | 2022-05-16 | Getters Spa | Antiviral composition comprising modified zeolites |
IT202100016025A1 (it) * | 2021-06-18 | 2022-12-18 | Argochem S R L | Rivestimento antibatterico e antivirale per superfici |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05105609A (ja) * | 1991-10-16 | 1993-04-27 | Shinagawa Fuel Co Ltd | 殺菌剤 |
JPH06263916A (ja) * | 1993-03-12 | 1994-09-20 | Toagosei Chem Ind Co Ltd | 抗菌剤及び抗菌性樹脂組成物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3930000A (en) * | 1971-06-16 | 1975-12-30 | Univ Washington | Silver-zinc allantoinate compositions and method of killing bacteria and fungi therewith |
JP3201023B2 (ja) * | 1992-11-17 | 2001-08-20 | 東亞合成株式会社 | 抗菌性合成繊維の製造方法 |
US6296863B1 (en) * | 1998-11-23 | 2001-10-02 | Agion Technologies, Llc | Antimicrobial fabric and medical graft of the fabric |
US6187456B1 (en) * | 1999-04-09 | 2001-02-13 | Milliken & Company | Method of inhibiting color change in a plastic article comprising silver-based antimicrobials |
-
2003
- 2003-10-31 US US10/576,012 patent/US20070026087A1/en not_active Abandoned
- 2003-10-31 EP EP03818872.8A patent/EP1676582B1/en not_active Expired - Lifetime
- 2003-10-31 AU AU2003304507A patent/AU2003304507A1/en not_active Abandoned
- 2003-10-31 JP JP2005509617A patent/JPWO2005037296A1/ja active Pending
- 2003-10-31 CN CNB200380110541XA patent/CN100500162C/zh not_active Expired - Lifetime
- 2003-10-31 WO PCT/JP2003/014008 patent/WO2005037296A1/ja active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05105609A (ja) * | 1991-10-16 | 1993-04-27 | Shinagawa Fuel Co Ltd | 殺菌剤 |
JPH06263916A (ja) * | 1993-03-12 | 1994-09-20 | Toagosei Chem Ind Co Ltd | 抗菌剤及び抗菌性樹脂組成物 |
Non-Patent Citations (2)
Title |
---|
RENTZ DO COMM CNMO E. J.: "Viral pathogens and severe acute respiratory syndrome: oligodynamic Ag+ for direct immune intervention", JOURNAL OF NUTRITIONAL & ENVIRONMENTAL MEDICINE, vol. 13, no. 2, 2003, pages 109 - 118, XP009022135 * |
See also references of EP1676582A4 * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007106876A (ja) * | 2005-10-13 | 2007-04-26 | Tottori Univ | 抗ウィルス性塗料組成物および塗装物 |
US20070243263A1 (en) * | 2006-04-14 | 2007-10-18 | Agion Technologies, Inc. | Antiviral Methods |
JP2010505887A (ja) * | 2006-10-12 | 2010-02-25 | エヌエム テック ナノマテリアルズ マイクロディバイス テクノロジー リミテッド | 抗微生物性を有する組成物を含む材料、アイテム及び製品 |
JP7008914B2 (ja) | 2015-03-31 | 2022-01-25 | 住化エンバイロメンタルサイエンス株式会社 | 抗ウイルス組成物 |
JP2016190808A (ja) * | 2015-03-31 | 2016-11-10 | 住化エンバイロメンタルサイエンス株式会社 | 抗ウイルス組成物 |
WO2017150063A1 (ja) * | 2016-03-01 | 2017-09-08 | 東亞合成株式会社 | 抗ウイルス剤、コーティング組成物、樹脂組成物及び抗ウイルス製品 |
JPWO2017150063A1 (ja) * | 2016-03-01 | 2019-01-24 | 東亞合成株式会社 | 抗ウイルス剤、コーティング組成物、樹脂組成物及び抗ウイルス製品 |
JP2018172306A (ja) * | 2017-03-31 | 2018-11-08 | 住化エンバイロメンタルサイエンス株式会社 | 抗ウイルス性コーティング剤 |
WO2022025136A1 (ja) * | 2020-07-30 | 2022-02-03 | 大日本印刷株式会社 | 抗ウイルス性物品及び抗ウイルス性樹脂組成物 |
JP2022174258A (ja) * | 2020-07-30 | 2022-11-22 | 大日本印刷株式会社 | 抗ウイルス性物品及び抗ウイルス性樹脂組成物 |
JP7226480B2 (ja) | 2020-07-30 | 2023-02-21 | 大日本印刷株式会社 | 抗ウイルス性物品及び抗ウイルス性樹脂組成物 |
JP2022027514A (ja) * | 2020-07-30 | 2022-02-10 | 大日本印刷株式会社 | 抗ウイルス性物品及び抗ウイルス性樹脂組成物 |
JP2021181227A (ja) * | 2020-07-30 | 2021-11-25 | 大日本印刷株式会社 | 抗ウイルス性物品及び抗ウイルス性樹脂組成物 |
JP7226635B2 (ja) | 2020-07-30 | 2023-02-21 | 大日本印刷株式会社 | 抗ウイルス性物品及び抗ウイルス性樹脂組成物 |
JP7211458B2 (ja) | 2020-07-30 | 2023-01-24 | 大日本印刷株式会社 | 抗ウイルス性物品及び抗ウイルス性物品の製造方法 |
WO2022079997A1 (ja) * | 2020-10-15 | 2022-04-21 | Dr.C医薬株式会社 | 殺コロナウイルス剤並びにそれを用いた方法及び用途 |
JPWO2022079997A1 (ja) * | 2020-10-15 | 2022-04-21 | ||
JP2022075278A (ja) * | 2020-11-06 | 2022-05-18 | 一般財団法人新医療財団 | コロナウイルス(例えば、SARS-CoV-2)を含む広範な微生物に有用な抗微生物剤 |
WO2022097729A1 (ja) * | 2020-11-06 | 2022-05-12 | 一般財団法人新医療財団 | コロナウイルス(例えば、SARS-CoV-2)を含む広範な微生物に有用な抗微生物剤 |
JP6884447B1 (ja) * | 2020-11-06 | 2021-06-09 | 一般財団法人新医療財団 | コロナウイルス(例えば、SARS−CoV−2)を含む広範な微生物に有用な抗微生物剤 |
WO2023021768A1 (ja) * | 2021-08-18 | 2023-02-23 | 株式会社ダイセル | 抗ウイルス性成形体およびその用途 |
JP2023027804A (ja) * | 2021-08-18 | 2023-03-03 | 株式会社ダイセル | 抗ウイルス性成形体およびその用途 |
Also Published As
Publication number | Publication date |
---|---|
EP1676582B1 (en) | 2014-12-24 |
EP1676582A4 (en) | 2007-10-31 |
CN100500162C (zh) | 2009-06-17 |
AU2003304507A1 (en) | 2005-05-05 |
JPWO2005037296A1 (ja) | 2006-12-28 |
US20070026087A1 (en) | 2007-02-01 |
EP1676582A1 (en) | 2006-07-05 |
CN1859919A (zh) | 2006-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005037296A1 (ja) | 抗コロナウイルス剤 | |
US20100233245A1 (en) | Nanoparticle composition and process thereof | |
EP2480499B1 (en) | Biocidal colloidal dispersions of silica particles with silver ions adsorbed thereon | |
Le et al. | Powerful colloidal silver nanoparticles for the prevention of gastrointestinal bacterial infections | |
JP2022500361A (ja) | 抗病原性組成物およびその方法 | |
Luceri et al. | Silver nanoparticles: review of antiviral properties, mechanism of action and applications | |
CN105517956B (zh) | 用于除去多种微生物的经官能团改性并在其表面吸附柠檬酸提取物的纳米颗粒二氧化钛纳米材料 | |
Jiang et al. | Bactericidal mechanisms and effector targets of TiO 2 and Ag-TiO 2 against Staphylococcus aureus | |
WO2010136792A2 (en) | Antibacterial composition | |
Liu et al. | Antimicrobial polymeric composites for high-touch surfaces in healthcare applications | |
CN105777792B (zh) | 一种季铵盐化荧光硅点及其制备方法与应用 | |
Baselga et al. | Silver nanoparticles–polyethyleneimine-based coatings with antiviral activity against SARS-CoV-2: a new method to functionalize filtration media | |
Rius-Rocabert et al. | Broad virus inactivation using inorganic micro/nano-particulate materials | |
Siwal et al. | Antimicrobial materials: new strategies to tackle various pandemics | |
Ghosh et al. | Permanent, antimicrobial coating to rapidly kill and prevent transmission of bacteria, fungi, influenza, and SARS-CoV-2 | |
Assis et al. | Polypropylene modified with Ag-based semiconductors as a potential material against SARS-CoV-2 and other pathogens | |
Ismail et al. | Transparent nanocrystallite silver for antibacterial coating | |
JP3197308B2 (ja) | 殺菌剤 | |
JPH05195438A (ja) | 抗菌防臭繊維 | |
WO2010015801A2 (en) | Biocidal composition | |
CN101094896A (zh) | 氢氧化钙的新用途 | |
Guerrero-Arguero et al. | Mitigation of SARS-CoV-2 by using transition metal Nanozeolites and quaternary ammonium compounds as antiviral agents in suspensions and soft fabric materials | |
Patel | Antimicrobial paper embedded with nanoparticles as spread-breaker for corona virus | |
JPH07316009A (ja) | 抗菌抗ウイルス抗黴剤およびその複合体 | |
CN218389867U (zh) | 一种抗病毒口罩 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200380110541.X Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003818872 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005509617 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007026087 Country of ref document: US Ref document number: 10576012 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2003818872 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10576012 Country of ref document: US |